Patient or Disabled Group
Pfizer Launches PfizerForAll: A Digital Platform to Simplify Healthcare Access
PfizerForAll, digital healthcare platform, telehealth, COVID-19, flu, migraines, healthcare access, patient support services
Galapagos Halts CAR-T Cell Therapy Trial Due to Parkinsonism Case
Galapagos, CAR-T cell therapy, Parkinsonism, clinical trial, patient enrollment, BCMA-directed therapy, multiple myeloma
Sanofi Invests €1.3 Billion in New Insulin Manufacturing Plant in Frankfurt
Sanofi, insulin manufacturing, Frankfurt, €1.3 billion, BioCampus, digital solutions, diabetes patients, European supply chain
GLP-1s May Cut Risk of 10 Obesity-Related Cancers in Diabetes Patients: Study
GLP-1, Obesity-Related Cancers, Diabetes Patients, Cancer Prevention, Weight Loss
Fresenius Medical Care Achieves 25x Faster Kidney Disease Insights with Privacy Analytics
Fresenius Medical Care, kidney disease, data analytics, patient privacy, global database, healthcare insights
Sarepta Therapeutics: Next Steps After Full FDA Approval for Duchenne Muscular Dystrophy Gene Therapy
Sarepta Therapeutics, Duchenne muscular dystrophy, gene therapy, FDA approval, Elevidys, microdystrophin, ambulatory patients, non-ambulatory patients, pipeline development, rare diseases, genetic medicine.
Three Ways to Solve the Patient Support Paradox
Patient Support Paradox, Patient Experience, Healthcare, Patient Flow, Patient Engagement
Navigating the Complexities of Adding Rare Disease Products to Your Company’s Portfolio
Rare disease products, biopharmaceutical development, commercialization, market access, patient identification, payer contract strategy, value-based contracting, regulatory incentives, emerging technology.
Revolutionizing Clinical Trials: Leveraging AI for Enhanced Efficiency and Accuracy
Artificial Intelligence, Clinical Trials, Data Analysis, Patient Recruitment, Personalized Medicine, AI-Powered Tools, Medical Research, Efficiency, Accuracy
Sanofi’s Sarclisa Achieves First-in-Class Win, Poised to Surpass J&J in Multiple Myeloma Treatment
Sarclisa, Sanofi, multiple myeloma, J&J, ASCO, IMROZ study, anti-CD38 therapy, VRd, transplant-ineligible patients